The induction of mixed chimerism using ES cell-derived hematopoietic stem cells

Francesca Milanetti; You Hong Cheng; Richard K. Burt

doi:10.1007/978-1-4614-5480-9_12

The induction of mixed chimerism using ES cell-derived hematopoietic stem cells

Francesca Milanetti, You Hong Cheng, Richard K. Burt^*

^*Corresponding author for this work

Medicine, Immunotherapy for Autoimmune Disease Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The use of hematopoietic stem cell (HSC) transplantation for the establishment of mixed chimerism generally leads to durable immune tolerance to allografts in animal models of transplantation. The development of reduced intensity regimens for achieving allogeneic hematopoietic engraftment across major histocompatibility complex (MHC) barriers and its recent application in clinical trials of kidney transplantation is encouraging. Embryonic stem cell-derived HSCs have lower immunogenicity and could, therefore, potentially be safer, inducing mixed chimerism and tolerance with minimal host pre-treatment and risk of graft versus host disease, despite crossing MHC barriers.

Original language	English (US)
Title of host publication	The Immunological Barriers to Regenerative Medicine
Publisher	Springer New York
Pages	225-255
Number of pages	31
ISBN (Electronic)	9781461454809
ISBN (Print)	9781461454793
DOIs	https://doi.org/10.1007/978-1-4614-5480-9_12
State	Published - Jan 1 2013

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1007/978-1-4614-5480-9_12

Cite this

@inbook{eabc6f87711d4d93bf1c8a0429b4724c,

title = "The induction of mixed chimerism using ES cell-derived hematopoietic stem cells",

abstract = "The use of hematopoietic stem cell (HSC) transplantation for the establishment of mixed chimerism generally leads to durable immune tolerance to allografts in animal models of transplantation. The development of reduced intensity regimens for achieving allogeneic hematopoietic engraftment across major histocompatibility complex (MHC) barriers and its recent application in clinical trials of kidney transplantation is encouraging. Embryonic stem cell-derived HSCs have lower immunogenicity and could, therefore, potentially be safer, inducing mixed chimerism and tolerance with minimal host pre-treatment and risk of graft versus host disease, despite crossing MHC barriers.",

author = "Francesca Milanetti and Cheng, {You Hong} and Burt, {Richard K.}",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-1-4614-5480-9_12",

language = "English (US)",

isbn = "9781461454793",

pages = "225--255",

booktitle = "The Immunological Barriers to Regenerative Medicine",

publisher = "Springer New York",

}

TY - CHAP

T1 - The induction of mixed chimerism using ES cell-derived hematopoietic stem cells

AU - Milanetti, Francesca

AU - Cheng, You Hong

AU - Burt, Richard K.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The use of hematopoietic stem cell (HSC) transplantation for the establishment of mixed chimerism generally leads to durable immune tolerance to allografts in animal models of transplantation. The development of reduced intensity regimens for achieving allogeneic hematopoietic engraftment across major histocompatibility complex (MHC) barriers and its recent application in clinical trials of kidney transplantation is encouraging. Embryonic stem cell-derived HSCs have lower immunogenicity and could, therefore, potentially be safer, inducing mixed chimerism and tolerance with minimal host pre-treatment and risk of graft versus host disease, despite crossing MHC barriers.

AB - The use of hematopoietic stem cell (HSC) transplantation for the establishment of mixed chimerism generally leads to durable immune tolerance to allografts in animal models of transplantation. The development of reduced intensity regimens for achieving allogeneic hematopoietic engraftment across major histocompatibility complex (MHC) barriers and its recent application in clinical trials of kidney transplantation is encouraging. Embryonic stem cell-derived HSCs have lower immunogenicity and could, therefore, potentially be safer, inducing mixed chimerism and tolerance with minimal host pre-treatment and risk of graft versus host disease, despite crossing MHC barriers.

UR - http://www.scopus.com/inward/record.url?scp=85028500555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028500555&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-5480-9_12

DO - 10.1007/978-1-4614-5480-9_12

M3 - Chapter

AN - SCOPUS:85028500555

SN - 9781461454793

SP - 225

EP - 255

BT - The Immunological Barriers to Regenerative Medicine

PB - Springer New York

ER -

The induction of mixed chimerism using ES cell-derived hematopoietic stem cells

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this